Cargando…

Clinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization

OBJECTIVES: To compare best corrected visual acuity (BCVA), central macular thickness (CMT), and central choroidal thickness (CCT) in patients with type 2 macular telangiectasia (MacTel 2) and a control group and to evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Çoban Karataş, Müge, Yılmaz, Gürsel, Yüce Sezen, Aslıhan, Sarıtürk, Çağla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876777/ https://www.ncbi.nlm.nih.gov/pubmed/35196839 http://dx.doi.org/10.4274/tjo.galenos.2021.75608

Ejemplares similares

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Anti-Vascular Endothelial Growth Factor Treatment for Proliferative Macular Telangiectasia Type 2
por: Alkin, Zeynep, et al.
Publicado: (2016)

Impact of macular fluid features on outcomes of anti-vascular endothelial growth factor treatment for type 3 macular neovascularization
por: Yoon, Wontae, et al.
Publicado: (2021)

Type-3 macular neovascularization in a case of long-standing macular telangiectasia type-2
por: Chandran, Kiran, et al.
Publicado: (2023)

CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS
por: Osaka, Rie, et al.
Publicado: (2018)

Type 1 Idiopathic Macular Telangiectasia Associated with Type 3 Neovascularization
por: Tilleul, Julien, et al.
Publicado: (2014)

Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2
por: Gonzalez Martinez, Orlando G, et al.
Publicado: (2023)

Demographic Features of Idiopathic Macular Telangiectasia in Korean Patients
por: Kim, Sung Hyun, et al.
Publicado: (2015)

Optical coherence tomographic features of macular telangiectasia type 2: Korean Macular Telangiectasia Type 2 Study—Report No. 1
por: Kim, Young Ho, et al.
Publicado: (2020)

When is macular edema not macular edema? An update on macular telangiectasia type 2
por: Wu, Lihteh
Publicado: (2015)

Choroidal vascularity index change in macular telangiectasia type 2
por: Chun, Heejeong, et al.
Publicado: (2022)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat, Davis, et al.
Publicado: (2020)

Optical Coherence Tomography Angiography of Macular Telangiectasia Type 2 with Associated Subretinal Neovascular Membrane
por: Villegas, Victor M., et al.
Publicado: (2017)

Ischemic Retinopathy and Neovascular Proliferation Secondary to Severe Head Injury
por: Coban-Karatas, Muge, et al.
Publicado: (2014)

Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
por: Barış, Mine Esen, et al.
Publicado: (2020)

Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II
por: Enghelberg, Moises, et al.
Publicado: (2023)

Co occurrance of Macular Telangiectasia type 2 with hemorrhagic polypoidal choroidal vasculopathy and response to anti-vascular endothelial growth factor
por: Shah, Shreyas, et al.
Publicado: (2023)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Structural-vascular-functional correlation in type 2 non-proliferative macular telangiectasia
por: Venkatesh, Ramesh, et al.
Publicado: (2022)

Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration
por: Upasani, Deepa, et al.
Publicado: (2021)

Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
por: Hanhart, Joel, et al.
Publicado: (2022)

Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment
por: Moon, Bo-Hyun, et al.
Publicado: (2023)

Management of Idiopathic Macular Telangiectasia Type 2
por: Khodabande, Alireza, et al.
Publicado: (2019)

Profiling neovascular age‐related macular degeneration choroidal neovascularization lesion response to anti‐vascular endothelial growth factor therapy using SSOCTA
por: Told, Reinhard, et al.
Publicado: (2020)

Macular neovascularization in eyes with pachydrusen
por: Teo, Kelvin Yi Chong, et al.
Publicado: (2021)

Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration
por: Hussain, Rehan M, et al.
Publicado: (2021)

Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting
por: Kataja, Maria, et al.
Publicado: (2018)

Molecular Biomarkers of Neovascular Age-Related Macular Degeneration With Incomplete Response to Anti-Vascular Endothelial Growth Factor Treatment
por: Mantel, Irmela, et al.
Publicado: (2020)

Efficacy of anti-vascular endothelial growth factor agents for treating neovascular age-related macular degeneration in vitrectomized eyes
por: Mun, Yongseok, et al.
Publicado: (2021)

Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting
por: Matsubara, Hisashi, et al.
Publicado: (2022)

Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration
por: Dhingra, Narendra, et al.
Publicado: (2022)

Ultra-Widefield Imaging of Peripheral Vascular Abnormalities in Idiopathic Macular Telangiectasia Type 1
por: Pollmann, André S., et al.
Publicado: (2021)

Predictors of limited early response to anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration with machine learning feature importance
por: Perkins, Scott W., et al.
Publicado: (2022)

Choroidal endothelial and macrophage gene expression in atrophic and neovascular macular degeneration
por: Voigt, Andrew P, et al.
Publicado: (2022)

Combined photodynamic therapy and intravitreal bevacizumab as primary treatment for subretinal neovascularization associated with type 2 idiopathic macular telangiectasia
por: Rishi, Pukhraj, et al.
Publicado: (2009)

Analysis of candidate genes for macular telangiectasia type 2
por: Parmalee, Nancy L., et al.
Publicado: (2010)

Unusual Presentation of Type 1 Idiopathic Macular Telangiectasia
por: Bentaleb Machkour, Zaïnab, et al.
Publicado: (2017)

FLUORESCENCE LIFETIME PATTERNS IN MACULAR TELANGIECTASIA TYPE 2
por: Solberg, Yasmin, et al.
Publicado: (2020)

Right-angled vessels in macular telangiectasia type 2
por: Tzaridis, Simone, et al.
Publicado: (2021)

Relevance of Multicolor Imaging in Type 2 Macular Telangiectasia
por: Venkatesh, Ramesh, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nadj8kougtfl7sgaoi9e0kluth